Envarsus

DRUG9 trials

Sponsors

University Hospital Birmingham NHS Foundation Trust, Baylor Research Institute, California Institute of Renal Research, University of California, Davis, Medical University of Warsaw

Conditions

Compliance, PatientDrug ToxicityEnd Stage Renal DiseaseGraft FailureHeart Transplant RejectionImmune System SuppressionImmunosuppressionKidney Transplant Failure and Rejection

Phase 1

Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients

California Institute of Renal ResearchKidney Transplant; Complications, Kidney Transplant Failure and Rejection

Start: 2018-07-11End: 2023-12-31Target: 50Updated: 2023-02-09

Phase 2

Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen

CompletedNCT03373227

Baylor Research InstituteCompliance, Patient, Graft Failure, Heart Transplant Rejection

Start: 2017-12-04End: 2023-12-30Updated: 2025-10-08

Phase 4

AGe-adapted Benefits of Envarsus Versus Twice-daily Tacrolimus ImmunosuppressioN druGs After Kidney Transplantation

University Hospital Birmingham NHS Foundation TrustKidney Transplant Failure and Rejection

Start: 2017-04-30End: 2019-10-31Target: 40Updated: 2016-12-29

Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients

CompletedNCT03461445

University of California, DavisDrug Toxicity, Kidney Transplant; Complications, Neurotoxicity +1

Start: 2018-04-01End: 2023-07-31Updated: 2025-04-08

Envarsus Neurotoxicity Burden in Liver Transplant Patients

CompletedNCT03823768

Medical University of South CarolinaLiver Transplant; Complications, Neurotoxicity

Start: 2020-01-31End: 2024-01-30Updated: 2025-03-30

Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients

Enrolling by invitationNCT05655273

University Health Network, TorontoImmune System Suppression, Liver Transplant Rejection

Start: 2024-01-01End: 2026-02-28Target: 40Updated: 2024-12-11

Unknown Phase

Comparison of Safety and Efficacy of Two Variants of Prolonged - Released Tacrolimus (Advagraf vs. Envarsus ) in Patients After Liver Transplantation : Single Center Randomised Control Trial

Medical University of WarsawImmunosuppression, Liver Transplant Rejection

Start: 2018-07-09End: 2023-07-09Target: 200Updated: 2018-07-27

Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Immediate Release Tacrolimus to Slow Release Envarsus

CompletedNCT03703154

University of Kansas Medical CenterEnd Stage Renal Disease

Start: 2018-10-25End: 2021-03-03Updated: 2021-04-27

ENvarsus for Impaired Glucose Tolerance Post REnal transplAnT

WithdrawnNCT04973982

Barts & The London NHS TrustRenal Transplant Failure

Start: 2022-01-31End: 2022-10-01Updated: 2022-04-01

Related Papers

Results of a Randomized Controlled Trial Evaluating the Impact of Conversion to LCP Tacrolimus on Neurologic Toxicities in Liver Transplant Recipients.

2025-10-06